News and information about DAMIAN and Primary Aldosteronism. 

At DAMIAN, we’re about passion, not convenience.

Teresa Gerlock
Chief Operating Officer
  • DAMIAN announces publication in the British Journal of Clinical Pharmacology of phase 1 data of dexfadrostat phosphate in healthy volunteers

    Today DAMIAN announces the publication of study DP13C101, a phase 1 study evaluating the efficacy and safety of dexfadrostat phosphate in healthy volunteers in the British Journal of Clinical Pharmacology.

    Dexfadrostat phosphate is a novel aldosterone synthase inhibitor (ASI), which acts to directly control the production of aldosterone at its origin. “By inhibiting the 3 enzymatic conversions mediated by aldosterone synthase, dexfadrostat phosphate was shown to demonstrate a dose-dependent reduction of the aldosterone-to-renin ratio (ARR, a marker of sodium retention) without affecting the adrenal stress response or the hypothalamic-pituitary-gonadal axis.”

    DAMIAN announced in October 2022 the successful completion of a phase 2 study evaluating dexfadrostat phosphate in patients with primary aldosteronism. The study met both its primary endpoints (ARR, ambulatory systolic blood pressure reduction) with high statistical significance following 8 weeks of once-daily treatment. The study also demonstrated a good safety and tolerability profile.

    Mulatero et al., Brit J Clinical Pharmacol. 2023 Mar 13; doi: 10.1111/bcp.15713. Online ahead of print

  • DAMIAN receives research grant from Innosuisse

    Innosuisse awards third Swiss research grant to DAMIAN to support the further development of its new research project DP20. The new funding supports a collaboration between DAMIAN and its three research partners: Fachhochschule Nordwest Schweiz, ETH Zurich and the University of Bern.

  • DAMIAN announces dexfadrostat phosphate achieves high efficacy in PA patients

    DAMIAN announces new data from the Phase II trial in patients with primary aldosteronism (PA), that showed the investigational compound dexfadrostat phosphate effectively reduced both aldosterone-to-renin ratio (ARR) and ambulatory systolic blood pressure (aSBP). The trial met both primary endpoints with high significance.

  • DAMIAN successfully completes Phase II study of dexfadrostat phosphate (DP13)

    DAMIAN completed the first Phase II study of an aldosterone synthase inhibitor in patients with primary aldosteronism using its novel compound, dexfadrostat phosphate (DP13), in May 2022.  

  • DAMIAN clinical plan affirmed by the Foundation for Therapeutic Research

    The Lausanne-based Foundation for Therapeutic Research awards a grant for the development of new therapeutic principles in cardiovascular disease to the University of Torino to investigate dexfadrostat phosphate (DP13). The grant supports the Phase I clinical trial of dexfadrostat phosphate, the first-in-class aldosterone synthase inhibitor from DAMIAN.

  • DAMIAN conducts Phase I study of dexfadrostat phosphate (DP13) 

    DAMIAN executes its Phase I proof-of-concept, double-blind, safety and tolerability study of dexfadrostat phosphate in healthy volunteers (NCT03046589). The Phase I study successfully completed in September 2018.

  • DAMIAN initiates Phase II study of dexfadrostat phosphate (DP13) 

    DAMIAN enrolls the first patients in its multinational Phase II study of dexfadrostat phosphate in patients with Primary Aldosteronism (NCT04007406; EUDRACT# 2019-000919-85).

  • DAMIAN receives research grant from Innosuisse (formerly CTI)

    Innosuisse awards second Swiss research grant to DAMIAN to support the further development of its diagnostic tool, DP14. The new funding follows the successful completion of the design phase and allows the team to execute the in vivo proof-of-concept experiments.

  • Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study

    This study by Hundemer et al. evaluated the electronic health records of PA patients on mineralocorticoid receptor antagonist (MRA) therapy and matched hypertensives to investigate the risk of cardiovascular events. The study demonstrated that in PA patients, the risks were higher than in patients with essential hypertension, independent of blood pressure control. The authors speculate that this may have to do, in part, with patients not responding adequately to MRA therapy.

    Hundemer et al., Lancet Diabetes Endocrinol. 2018 Jan;6(1):51-59; doi: 10.1016/S2213-8587(17)30367-4

  • Is primary aldosteronism still largely unrecognized?

    This review article highlights the disconnect between prospective, selective PA studies, which show a relatively high incidence rate, and real-world clinical data which demonstrate that PA remains under diagnosed and under treated. Diagnosis and referral rates remain low, despite the long-term risks associated with uncontrolled PA.

    Buffolo et al., Horm Metab Res. 2017;49:908-914; doi: 10.1055/s-0043-119755

  • Endocrine Society Guidelines for Primary Aldosteronism

    The Endocrine Society published an update to their clinical practice guidelines for management of patients with Primary Aldosteronism. These guidelines, based on data from systematic reviews and primary studies, provide an update to the recommendations of whom should be screened and the diagnostic pathway.

    J Clin Endocrinol Metab, May 2016, 101(5):1889 –1916; doi: 10.1210/jc.2015-4061